Apixaban to prevent stroke in patients with atrial fibrillation: a review.

Journal Article (Review)

Atrial fibrillation is a common, costly and morbid cardiovascular arrhythmia. Stroke prevention remains the mainstay of treatment for atrial fibrillation, and the recent advent of novel oral anticoagulants with direct factor IIa or factor Xa inhibition has significantly revolutionized this aspect of treatment for atrial fibrillation patients. This review focuses on the tolerability and efficacy of apixaban and tackles the generalizability of the findings with apixaban to broader patient populations than those primarily enrolled in the clinical trials, drawing from the AVERROES and ARISTOTLE trials and their subsequent secondary analyses. Taken together, findings from these trials show that apixaban is superior to warfarin in preventing stroke with a lower risk of major bleeding in the general population of patients with atrial fibrillation as well as in several key high-risk patient subgroups.

Full Text

Duke Authors

Cited Authors

  • Peterson, BE; Al-Khatib, SM; Granger, CB

Published Date

  • March 2017

Published In

Volume / Issue

  • 11 / 3

Start / End Page

  • 91 - 104

PubMed ID

  • 27342651

Electronic International Standard Serial Number (EISSN)

  • 1753-9455

International Standard Serial Number (ISSN)

  • 1753-9447

Digital Object Identifier (DOI)

  • 10.1177/1753944716652787

Language

  • eng